Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients

British Journal of Anaesthesia

Volumn 78, Issue 3, 1997, Pages 267-273

  Sparr, H J ^a   Wierda, J M K H ^b   Proost, J H ^b   Keller, C ^a   Khuenl Brady, K S ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Intensive care; Neuromuscular block, rocuronium; Pharmacodynamics; Pharmacokinetics, rocuronium

Indexed keywords

DRUG METABOLITE; ROCURONIUM;

ADOLESCENT; ADULT; AGED; ARTERIAL BLOOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROMUSCULAR BLOCKING; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0031057256     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/78.3.267     Document Type: Article

References (24)

1. Khuenl-Brady KS, Puehringer F, Koller J, Mitterschiffthaler G. Evaluation of the time course of action of maintenance doses of rocuronium (ORG 9426) under halothane anaesthesia. Acta Anaesthesiologica Scandinavica 1993; 37: 137-139.
2. Sparr HJ, Khuenl-Brady KS, Eriksson LI. Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. European Journal of Anaesthesiology 1994; 11 (Suppl. 9): 63-65.
3. McCoy EP, Mirakhur RK, Maddineni VR, Wierda JMKH, Proost JH. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. British Journal of Anaesthesia 1996; 76: 29-33.
4. Wierda JMKH, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Canadian Journal of Anaesthesia 1991; 38: 430-435.
5. Wierda JMKH, Proost JH. The pharmacokinetics and the pharmacokinetic-dynamic relationship of rocuronium bromide. Anaesthetic Pharmacology Review 1995; 3: 192-201.
6. Wright PMC, Hart P, Lau M, Sharma ML, Gruenke L, Fisher DM. Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. Anesthesiology 1994; 81: 59-68.
7. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. New England Journal of Medicine 1992; 327: 524-528.
8. Elliot JM, Bion JF. The use of neuromuscular blocking drugs in the intensive care practice. Acta Anaesthesiologica Scandinavica 1995; 39: 70-82.
9. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Critical Care Medicine 1994; 22: 884-893.
10. Meyer KC, Prielipp RC, Grossmann JE, Coursin DB. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesthesia and Analgesia 1994; 78: 722-724.
11. Agoston S, Seyr M, Khuenl-Brady KS, Henning RH. Use of neuromuscular blocking agents in the intensive care unit. Anesthesiology Clinics of North America 1993; 11: 345-359.
12. Viby-Mogensen J. Monitoring neuromuscular function in the intensive care unit. Intensive Care Medicine 1993; 19 (Suppl. 2): 74-79.
13. Kleef UW, Proost JH, Roggeveld J, Wierda JMKH. Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. Journal of Chromatography 1993; 621: 65-67.
14. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical Recipes. Cambridge: Cambridge University Press, 1986.
15. Boxenbaum HG, Riegelman S, ElashoffRM. Statistical estimations in pharmakokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1974; 2: 123-148.
16. Wagner JG. Fundamentals of Clinical Pharmacokinetics. Hamilton, Illinois: Drug Intelligence Publications, 1975.
17. Shanks CA, Fragen RJ, Ling D. Continuous intravenous infusion of rocuronium (ORG 9426) in patients receiving balanced, enflurane, or isoflurane anesthesia. Anesthesiology 1993; 78: 649-651.
18. Olkkola KT, Tammisto T. Quantifying the interaction of rocuronium (Org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental, and isoflurane using closed-loop feedback control of rocuronium infusion. Anesthesia and Analgesia 1994; 78: 691-696.
19. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ, Vender J, Howard D, Casale EJ, Murray MJ. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesthesia and Analgesia 1995; 81: 3-12.
20. Cantineau JP, Porte F, D'Honneur G, Duvaldestin P. Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anesthetized patients. Anesthesiology 1994; 81: 585-590.
21. Werba A, Klezl M, Schramm W, Langenecker S, Müller C, Gosch M, Spiss CK. The level of neuromuscular block needed to supress diaphragmatic movement during tracheal suction in patients with raised intracranial pressure: a study with vecuronium and atracurium. Anaesthesia 1993; 48: 301-303.
22. McCoy EP, Mirakhur RK, Maddineni VR, Loan PB, Connolly F. Administration of rocuronium (Org 9426) by continuous infusion and its reversibility with anticholinesterases. Anaesthesia 1994; 49: 940-945.
23. Loan PB, Paxton LD, Mirakhur RK, Connolly F, McCoy EP. The TOF-Guard neuromuscular transmission monitor. A comparison with the Myograph 2000. Anaesthesia 1995; 50: 699-702.
24. Lauven PM, Stoeckel H, Schwilden H. Ein pharmakokinetisch begründetes Infusionsmodell für Midazolam. Eine mikroprozessorgesteuerte Applikationsform zur Erreichung konstanter Plasmaspiegel. Der Anaesthesist 1982; 31: 15-20.